Kinetic analyses of [123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: A critical evaluation of the single-scan approach

NeuroImage

Volumn 42, Issue 2, 2008, Pages 548-558

  Meyer, Philipp T ^a   Sattler, Bernhard ^b   Winz, Oliver H ^a   Fundke, Rico ^b   Oehlwein, Christian ^c   Kendziorra, Kai ^b   Hesse, Swen ^b   Schaefer, Wolfgang M ^a   Sabri, Osama ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c Outpatient Practice for Movement Disorders ^*  (Germany)

Author keywords

123I IBZM; Dopamine D2 receptor; SPECT; Tracer kinetic analysis

Indexed keywords

DOPAMINE 2 RECEPTOR; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; PYRROLIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; KINETICS; MALE; MOTOR DYSFUNCTION; NOISE; PRIORITY JOURNAL; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS; STRIATE CORTEX; CORPUS STRIATUM; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; PROTEIN BINDING; SCINTISCANNING;

ADULT; AGED; BENZAMIDES; CORPUS STRIATUM; FEMALE; HUMANS; KINETICS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MOVEMENT DISORDERS; PROTEIN BINDING; PYRROLIDINES; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 48149092098     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2008.05.023     Document Type: Article

References (33)

1. Abi-Dargham A., Kegeles L.S., Zea-Ponce Y., Mawlawi O., Martinez D., Mitropoulou V., O'Flynn K., Koenigsberg H.W., Van Heertum R., Cooper T., Laruelle M., and Siever L.J. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol. Psychiatry 55 (2004) 1001-1006
2. Acton P.D., Pilowsky L.S., Suckling J., Brammer M.J., and Ell P.J. Registration of dynamic dopamine D2 receptor images using principal component analysis. Eur. J. Nucl. Med. 24 (1997) 1405-1412
3. Brücke T., Podreka I., Angelberger P., Wenger S., Topitz A., Küfferle B., Müller C., and Deecke L. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J. Cereb. Blood Flow Metab. 11 (1991) 220-228
4. Camps M., Kelly P.H., and Palacios J.M. Autoradiographic localization of dopamine D 1 and D 2 receptors in the brain of several mammalian species. J. Neural. Transm. Gen. Sect. 80 (1990) 105-127
5. Carson R.E., Channing M.A., Blasberg R.G., Dunn B.B., Cohen R.M., Rice K.C., and Herscovitch P. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J. Cereb. Blood Flow Metab. 13 (1993) 24-42
6. Carson R.E., Breier A., de Bartolomeis A., Saunders R.C., Su T.P., Schmall B., Der M.G., Pickar D., and Eckelman W.C. Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J. Cereb. Blood Flow Metab. 17 (1997) 437-447
7. Catafau A.M., Bullich S., Danús M., Penengo M.M., Cot A., Abanades S., Farré M., Pavía J., and Ros D. Test-retest variability and reliability of 123I-IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms. Synapse 62 (2008) 62-69
8. Collins D.L., Neelin P., Peters T.M., and Evans A.C. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J. Comput. Assist. Tomogr. 18 (1994) 192-205
9. Costa D.C., Verhoeff N.P., Cullum I.D., Ell P.J., Syed G.M., Barrett J., Palazidou E., Toone B., Van Royen E., and Bobeldijk M. In vivo characterisation of 3-iodo-6-methoxybenzamide 123I in humans. Eur. J. Nucl. Med. 16 (1990) 813-816
10. Farde L., Hall H., Ehrin E., and Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231 (1986) 258-261
11. Ichise M., Toyama H., Fornazzari L., Ballinger J.R., and Kirsh J.C. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J. Nucl. Med. 34 (1993) 1274-1281
12. Ichise M., Liow J.S., Lu J.Q., Takano A., Model K., Toyama H., Suhara T., Suzuki K., Innis R.B., and Carson R.E. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J. Cereb. Blood Flow Metab. 23 (2003) 1096-1112
13. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., and Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 27 (2007) 1533-1539
14. Ito H., Hietala J., Blomqvist G., Halldin C., and Farde L. Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J. Cereb. Blood Flow Metab. 18 (1998) 941-950
15. Kim Y.J., Ichise M., Ballinger J.R., Vines D., Erami S.S., Tatschida T., and Lang A.E. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov. Disord. 17 (2002) 303-312
16. Knable M.B., Jones D.W., Coppola R., Hyde T.M., Lee K.S., Gorey J., and Weinberger D.R. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. J. Nucl. Med. 36 (1995) 1216-1225
17. Knudsen G.M., Karlsborg M., Thomsen G., Krabbe K., Regeur L., Nygaard T., Videbaek C., and Werdelin L. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur. J. Nucl. Med. Mol. Imaging 31 (2004) 1631-1638
18. Kung H.F., Guo Y.Z., Billings J., Xu X., Mach R.H., Blau M., and Ackerhalt R.E. Preparation and biodistribution of [125I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. Int. J. Rad. Appl. Instrum. B 15 (1988) 195-201
19. Lammertsma A.A., and Hume S.P. Simplified reference tissue model for PET receptor studies. NeuroImage 4 (1996) 153-158
20. Laruelle M., Abi-Dargham A., van Dyck C.H., Rosenblatt W., Zea-Ponce Y., Zoghbi S.S., Baldwin R.M., Charney D.S., Hoffer P.B., Kung H.F., and Innis R.B. SPECT imaging of striatal dopamine release after amphetamine challenge. J. Nucl. Med. 36 (1995) 1182-1190
21. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., and Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9235-9240
22. Laruelle M., Iyer R.N., al-Tikriti M.S., Zea-Ponce Y., Malison R., Zoghbi S.S., Baldwin R.M., Kung H.F., Charney D.S., Hoffer P.B., Innis R.B., and Bradberry C.W. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25 (1997) 1-14
23. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., and Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 16 (1996) 834-840
24. Meyer P.T., Sattler B., Lincke T., Seese A., and Sabri O. Investigating dopaminergic neurotransmission with 123I-FP-CIT SPECT: comparability of modern SPECT systems. J. Nucl. Med. 44 (2003) 839-845
25. Meyer P.T., Elmenhorst D., Matusch A., Winz O., Zilles K., and Bauer A. 18F-CPFPX PET: on the generation of parametric images and the effect of scan duration. J. Nucl. Med. 47 (2006) 200-207
26. Nadeau S.E., Couch M.W., Devane C.L., and Shukla S.S. Regional analysis of D2 dopamine receptors in Parkinson's disease using SPECT and iodine-123-iodobenzamide. J. Nucl. Med. 36 (1995) 384-393
27. Seibyl J.P., Woods S.W., Zoghbi S.S., Baldwin R.M., Dey H.M., Goddard A.W., Zea-Ponce Y., Zubal G., Germine M., Smith E.O., Heninger G.R., Charney D.S., Kung H.F., Alavi A., Hoffer P.B., and Innis R.B. Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM. J. Nucl. Med. 33 (1992) 1964-1971
28. Slifstein M., and Laruelle M. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J. Nucl. Med. 41 (2000) 2083-2088
29. Tatsch K., Asenbaum S., Bartenstein P., Catafau A., Halldin C., Pilowsky L.S., Pupi A., and European Association of Nuclear Medicine. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) receptor ligands. Eur. J. Nucl. Med. Mol. Imaging 29 (2002) BP23-BP29
30. Toyama H., Ichise M., Ballinger J.R., Fornazzari L., and Kirsh J.C. Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans. Ann. Nucl. Med. 7 (1993) 29-38
31. Verhoeff N.P., Brücke T., Podreka I., Bobeldijk M., Angelberger P., and Van Royen E.A. Dynamic SPECT in two healthy volunteers to determine the optimal time for in vivo D2 dopamine receptor imaging with 123I-IBZM using the rotating gamma camera. Nucl. Med. Commun. 12 (1991) 687-697
32. Videbaek C., Toska K., Friberg L., Holm S., Angelo H.R., and Knudsen G.M. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography. J. Cereb. Blood Flow Metab. 21 (2001) 92-97
33. Wu Y., and Carson R.E. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J. Cereb. Blood Flow Metab. 22 (2002) 1440-1452